Q-omics provides the consensus-scored MEGF10 profile across patient tissues and cancer cell-line models. MEGF10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MEGF10 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MEGF10 RNA expression shows 16,661 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where MEGF10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEGF10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEGF10 survival associations across molecular data types. MEGF10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEGF10 RNA expression–survival associations across cancer types. High MEGF10 expression shows unfavorable associations in LGG, STAD and THCA, but favorable associations in UVM, LUSC and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MEGF10 RNA expression.
This table summarizes MEGF10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MEGF10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEGF10 shows lower tumor expression in KIRC, COAD, KIRP, KICH and LIHC and higher tumor expression in LUAD. The KIRC box plot shows higher MEGF10 RNA expression in normal versus tumor tissue (log2 FC = −0.153, t-test p < 0.001).
This table shows molecular features associated with MEGF10 in patient tissues and cancer cell lines. In patient samples, MEGF10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, MEGF10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
